NCT06804824 - A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors | Biotech Hunter

Enrollment

220

Participants

Timeline

Start Date

February 25, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2027

Conditions

Advanced Solid Tumors

Interventions

DRUG

VVD-159642

Oral capsules

DRUG

Sotorasib

Oral tablets

DRUG

Trametinib

Oral tablets

Trial Locations (9)

5000

RECRUITING

Clinical Research South Australia (CRSA), Adelaide

6009

RECRUITING

Linear Clinical, Nedlands

22031

RECRUITING

NEXT Virginia, Fairfax

49546

RECRUITING

START Mid West, Grand Rapids

75039

RECRUITING

NEXT Dallas, Irving

78229

RECRUITING

START San Antonio, San Antonio

78299

RECRUITING

NEXT San Antonio, San Antonio

78758

RECRUITING

NEXT Austin, Austin

84401

RECRUITING

START Mountain, Ogden

All Listed Sponsors

lead

Vividion Therapeutics, Inc.

INDUSTRY